SAR3419 in Acute Lymphoblastic Leukemia

Summary

Primary Objective: Participants achieving an Objective Response Rate Secondary Objectives: * Response duration * Progression Free Survival * Minimal residual disease * Safety * Pharmacokinetics

Timeline

Start

2011-10

Primary completion

2014-05

Completion

2014-05

Outcome

Outcome not reported

Stopped: “The study is stopped due to very modest activity compared to competitors”

Publications

• Carol H, Szymanska B, Evans K, Boehm I, Houghton PJ, Smith MA, Lock RB. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin Cancer Res. 2013 Apr 1;19(7):1795-805. doi: 10.1158/1078-0432.CCR-12-3613. Epub 2013 Feb 20.

Drugs

Indications